Moderna’s early coronavirus vaccine results lack crucial data

$%name Moderna’s early coronavirus vaccine results lack crucial data by Authcom, Nova Scotia\s Internet and Computing Solutions Provider in Kentville, Annapolis Valley$

Moderna’s early coronavirus vaccine results look promising, but they actually lack the crucial data that doctors and physicians working on COVID-19 therapies need.
The company’s Monday announcement left out key details that will only arrive once a full study is available, but it also sent its stock soaring ahead a new round of public stock offering.
Moderna did say that eight out of 45 volunteers who were inoculated with the RNA vaccine developed neutralizing antibodies for SARS-CoV-2.
Visit BGR’s homepage for more stories.

Moderna is one of the several companies working on a vaccine for the novel coronavirus, and it’s the first company to have started Phase 1 human trials for the drug. It’s also the closest to reaching Phase 2, and emergency use of the vaccine may be approved as soon as this fall if all goes well.

The first patients were inoculated with Moderna’s mRNA-1273 compound several weeks ago, and the company disclosed preliminary results a few days ago saying the drug generates an immune response comparable to the one seen in COVID-19 survivors. That’s the kind of good news the world has been waiting for. A vaccine will be key to stopping the spread of the disease. However, some researchers say that Moderna hasn’t actually shared any data of value to scientists, cherry-picking the information it chose to make public.

Continue reading…

Today’s Top Deals

Trending Right Now:

Moderna’s early coronavirus vaccine results lack crucial data originally appeared on BGR.com on Wed, 20 May 2020 at 15:06:58 EDT. Please see our terms for use of feeds.